Effects of Traditional Chinese Medicine on Outcomes in Patients With AECOPD Risk Window

Last updated: April 14, 2021
Sponsor: Henan University of Traditional Chinese Medicine
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04851093
TCM for AECOPD Risk Window
  • Ages 40-80
  • All Genders

Study Summary

This study aims to objectively evaluate the clinical efficacy and safety of Traditional Chinese Medicine in the treatment of AECOPD Risk Window, providing a basis for the formulation of TCM treatment plan with AECOPD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. A confirmed diagnosis of AECOPD Risk Window;
  2. Age ranges from 40 years to 80 years;
  3. Syndrome differentiation meets criteria of qi deficiency and internal cold fluidsyndrome, qi and yin deficiency and unclean phlegm heat syndrome, or lung and spleenqi deficiency and phlegm-damp amassing in lung syndrome;
  4. Without participations in other interventional trials in the previous one month;
  5. With the informed consent signed.

Exclusion

Exclusion Criteria:

  1. Pregnant and lactating women;
  2. Dementia, mental disorders and reluctant partners;
  3. Complicated with heart failure (NYHA Class IV), or Serious cardiac arrhythmias, orunstable hemodynamics;
  4. Current respiratory disorders other than COPD (e.g., bronchiectasis, activetuberculosis, pneumothorax, Pleural effusion, pulmonary thromboembolic, orNeuromuscular diseases affect respiratory movement function);
  5. Complicated with serious hepatic and renal diseases (liver cirrhosis, portalhypertension, bleeding of varicose veins, dialysis, or renal transplantation);
  6. Bedridden for various reasons;
  7. Allergic to the used medicine.

Study Design

Total Participants: 336
Study Start date:
March 15, 2021
Estimated Completion Date:
December 31, 2022

Study Description

The incidence, mortality, and prevalence of chronic obstructive pulmonary disease (COPD) are high, with a prevalence among people 40 years of age or older of 10.1% worldwide and 13.7% in China. COPD has become the third leading cause of death worldwide. Acute exacerbations of COPD (AECOPD) are important events in the management of COPD because they negatively impact health status, readmission, and disease progression.

Due to the non-random and non-accidental occurrence of AECOPD,with acute exacerbations occurring mainly in a centralized period after an acute exacerbation, and wide open to attack easily in this period, we call this "highly dangerous period" as "AECOPD Risk Window". The AECOPD Risk Window has persistent systemic inflammation and unstable lung function, which increases the risk of AECOPD recurrence and readmission.

At present, western medicine has relatively mature treatment measures for COPD at the acute exacerbation stage and stable stage, however, there is no specific guidance on the medication of AECOPD Risk Window. COPD have been effectively treated with Chinese medicine for a long time. The study of syndrome regularity of "AECOPD Risk Window" provides a basis for the formulation of syndrome differentiation plan.

This is a multi-center, randomized, double-blind, controlled trial to compare the efficacy of two therapies for patients with AECOPD Risk Window. 336 subjects will be randomly assigned in a 1:1 ratio to experimental group or control group for 8 weeks treatment and 18 weeks follow-up. On the basis of health education and conventional treatment, the experimental group will receive TCM granule according to the TCM syndrome, while the control group will receive TCM placebo granule according to the TCM syndrom. The primary outcomes are acute exacerbation rate in the AECOPD Risk Window, COPD Assessment Test (CAT) in the AECOPD Risk Window; and secondary outcomes are time to the first acute exacerbation, degree of acute exacerbation in the AECOPD Risk Window, acute exacerbation rate in the follow-up period, degree of acute exacerbation in the follow-up period, COPD Assessment Test (CAT) in the follow-up period, lung function, clinical symptom scores, mMRC, quality of life and index of security.

Connect with a study center

  • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

    Zhengzhou, Henan 450000
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.